Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association of VEGFA and CCL4L2 polymorphisms with hand-foot skin reaction and survival of regorafenib in Japanese patients with colorectal cancer.

Cancer chemotherapy and pharmacology - 1 Jul 2024

Ono Koutaro, Murase Remi, Matsumoto Natsumi, Kubota Yutaro, Ishida Hiroo, Fujita Ken-Ichi

Abstract excerpt

PURPOSE: Treatment with regorafenib, which inhibits vascular endothelial growth factor (VEGF) receptor, frequently results in hand-foot skin reaction (HFSR), requiring treatment discontinuation or dose reduction. In our prospective study of regorafenib on patients with metastatic colorectal cancer, 17% of patients developed grade 3 HFSR. Herein, we retrospectively examined genetic polymorphisms associated with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Chemokine CCL4

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to East Asian People

Share to Phenylurea Compounds

Share to Pyridines

Share to Vascular Endothelial Growth Factor A

Source

Identifiers

PMID: 38459188
DOI: 10.1007/s00280-024-04649-5

Genes

CCL4L2
VEGFA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of VEGFA and CCL4L2 polymorphisms with hand-foot skin reaction and survival of regorafenib in Japanese patients with colorectal cancer.PMID 38459188Read ↗

Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib.Semantic proximity Read ↗

Polymorphisms of FGFR Pathway-related Factors and Capecitabine-induced Hand-foot Syndrome in Japanese Patients With Colorectal Cancer.Semantic proximity Read ↗

Regorafenib Therapy as a Third-Line Treatment for Metastatic Colorectal Cancer: A Single Center Long Term ExperienceSemantic proximity Read ↗

Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program.Semantic proximity Read ↗

Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.Semantic proximity Read ↗

SNPs in the COX-2/PGES/EP signaling pathway are associated with risk of severe capecitabine-induced hand-foot syndrome.Semantic proximity Read ↗

Spermine-Related DNA Hypermethylation and Elevated Expression of Genes for Collagen Formation are Susceptible Factors for Chemotherapy-Induced Hand-Foot Syndrome in Chinese Colorectal Cancer PatientsSemantic proximity Read ↗

Hand-Foot Syndrome in Cancer Patients on Capecitabine: Examining Prevalence, Impacts, and Associated Risk Factors at a Cancer Centre in MalaysiaSemantic proximity Read ↗

A phase II study on the efficacy of regorafenib in treating patients with c-KIT-mutated metastatic malignant melanoma that progressed after previous treatment (KCSG-UN-14-13)Semantic proximity Read ↗

Polymorphisms of NF-κB pathway genes influence adverse drug reactions of gefitinib in NSCLC patients.Semantic proximity Read ↗

Biomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancer.Semantic proximity Read ↗

Exome array analysis of adverse reactions to fluoropyrimidine-based therapy for gastrointestinal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.